Bausch + Lomb Corporation (BLCO)

Market Cap	5.55B
Revenue (ttm)	4.79B
Net Income (ttm)	-317.00M
Shares Out	352.47M
EPS (ttm)	-0.90
PE Ratio	n/a
Forward PE	24.02
Dividend	n/a
Ex-Dividend Date	n/a

Volume	589,710
Open	15.77
Previous Close	15.89
Day's Range	15.65 - 16.07
52-Week Range	13.16 - 21.69
Beta	0.46
Analysts	Buy
Price Target	19.82 (+25.84%)
Earnings Date	Feb 19, 2025

About BLCO

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and ...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: May 6, 2022
• Employees: 13,300
• Stock Exchange: NYSE
• Ticker Symbol: BLCO
• Website: https://www.bausch.com

Financial Performance

In 2024, Bausch + Lomb's revenue was $4.79 billion, an increase of 15.56% compared to the previous year's $4.15 billion. Losses were -$317.00 million, 21.9% more than in 2023.

Analyst Forecast

According to 12 analysts, the average rating for BLCO stock is "Buy." The 12-month stock price forecast is $19.82, which is an increase of 25.84% from the latest price.

Price Target

$19.82

(25.84% upside)

Analyst Consensus: Buy